GSK, Angiochem to develop drugs for lysosomal disease symptoms

02/27/2012 | Reuters

GlaxoSmithKline and Angiochem agreed to develop treatments intended to relieve neurological symptoms related to lysosomal storage diseases. Angiochem could get more than $300 million, including as much as $31.5 million upfront, plus sales royalties.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Abbott
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health